Stocks · News reference
Takeda Pharmaceutical Co Affirms FY2026 GAAP EPS Guidance of $0.66; Affirms FY2026 GAAP Sales Guidance of $29.585B
Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 GAAP EPS guidance from $0.66 to $0.66. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 30, 2026, 7:47 AM
- Checked
- Jul 30, 2026, 7:46 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.
Read original at benzingaVinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’
Vinod Khosla says AI is revolutionizing drug discovery, but drug testing needs to catch up with more human-relevant methods.
Read original at benzingaDepartment Of Veterans Affairs Awards Takeda $5.6B Contract for Drugs And Biologicals Through 2031
https://sam.gov/opp/b8e3db55feb04369933f735cc6cda9aa/view
Read original at benzinga